SCHEMBL21522326

SCHEMBL21522326

CC(C)(C)OC(=O)NC1CCC(Oc2ccccn2)CC1

nearest known ligand 0.50

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
KDM1A O60341 1/20 0.50
MAOB P27338 1/20 0.50
CACNB4 O00305 1/20 0.50
CACNA1A O00555 1/20 0.50
CACNA1G O43497 1/20 0.50
CACNG3 O60359 1/20 0.50
CACNA1F O60840 1/20 0.50
CACNA1H O95180 1/20 0.50
CACNB3 P54284 1/20 0.50
CACNA2D1 P54289 1/20 0.50
CACNG7 P62955 1/20 0.50
CACNA1B Q00975 1/20 0.50
CACNA1D Q01668 1/20 0.50
CACNB1 Q02641 1/20 0.50
CACNG1 Q06432 1/20 0.50
CACNB2 Q08289 1/20 0.50
CACNA1S Q13698 1/20 0.50
CACNA1C Q13936 1/20 0.50
CACNA1E Q15878 1/20 0.50
CACNA2D4 Q7Z3S7 1/20 0.50

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL18615454 0.85 KDM1A (0.48) KDM1AMAOBCACNB4CACNA1ACACNA1G
SCHEMBL21853961 0.82 TNKS (0.53) EPHX2TNKSPARP2PARP1AVPR1A
SCHEMBL21522398 0.81 KDM1A (0.53) KDM1AMAOBEPHX2CKS1BSKP1
SCHEMBL22570099 0.81 KDM1A (0.53) KDM1AMAOBEPHX2CKS1BSKP1
SCHEMBL20357441 0.81 CACNB4 (0.49) KDM1AMAOBCACNB4CACNA1ACACNA1G
SCHEMBL18615725 0.81 CACNB4 (0.49) KDM1AMAOBCACNB4CACNA1ACACNA1G
SCHEMBL18615723 0.81 CACNB4 (0.49) KDM1AMAOBCACNB4CACNA1ACACNA1G
SCHEMBL2647959 0.81 KDM1A (0.62) KDM1AMAOBCACNB4CACNA1ACACNA1G
SCHEMBL14647010 0.81 KDM1A (0.62) KDM1AMAOBCACNB4CACNA1ACACNA1G
SCHEMBL20357227 0.81 CACNB4 (0.50) KDM1AMAOBCACNB4CACNA1ACACNA1G

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 13 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20250034120-A1 PYRIDAZINONES AS PARP7 INHIBITORS RIBON THERAPEUTICS, INC. 2025-01-30 US disclosed
EP-4234551-A2 PYRIDAZINONES AS PARP7 INHIBITORS Ribon Therapeutics Inc. (US) 2023-08-30 EP disclosed
US-20230192664-A1 PYRIDAZINONES AS PARP7 INHIBITORS ANKURA TRUST COMPANY, LLC, AS COLLATERAL TRUSTEE 2023-06-22 US disclosed
EP-3788040-B1 PYRIDAZINONES AS PARP7 INHIBITORS RIBON THERAPEUTICS INC (US) 2023-04-12 EP disclosed
US-11566020-B1 Pyridazinones as PARP7 inhibitors RIBON THERAPEUTICS, INC. (US) 2023-01-31 US disclosed
US-11014913-B2 Pyridazinones as PARP7 inhibitors RIBON THERAPEUTICS, INC. (US) 2021-05-25 US disclosed
EP-3788040-A1 PYRIDAZINONES AS PARP7 INHIBITORS Ribon Therapeutics Inc. (US) 2021-03-10 EP disclosed
CN-112424188-A Pyridazinones as PARP7 inhibitors 里邦医疗公司 2021-02-26 CN disclosed
US-20210024502-A1 PYRIDAZINONES AS PARP7 INHIBITORS ANKURA TRUST COMPANY, LLC, AS COLLATERAL TRUSTEE 2021-01-28 US disclosed
US-10870641-B2 Pyridazinones as PARP7 inhibitors RIBON THERAPEUTICS, INC. (US) 2020-12-22 US disclosed
US-20200123134-A1 PYRIDAZINONES AS PARP7 INHIBITORS ANKURA TRUST COMPANY, LLC, AS COLLATERAL TRUSTEE 2020-04-23 US disclosed
US-10550105-B2 Pyridazinones as PARP7 inhibitors Ribon Therapeutics Inc. (US) 2020-02-04 US disclosed
US-20190330194-A1 PYRIDAZINONES AS PARP7 INHIBITORS ANKURA TRUST COMPANY, LLC, AS COLLATERAL TRUSTEE 2019-10-31 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (9 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20210024502-A1 PYRIDAZINONES AS PARP7 INHIBITORS PARP2, PARP1, PARP4 KDM1A 798/4885MAOB 758/4885CACNB4 4800/4885
US-10550105-B2 Pyridazinones as PARP7 inhibitors PARP2, PARP1, PARP4 KDM1A 798/4885MAOB 758/4885CACNB4 4800/4885
US-20250034120-A1 PYRIDAZINONES AS PARP7 INHIBITORS PARP2, PARP1, PARP4 KDM1A 798/4885MAOB 758/4885CACNB4 4800/4885
US-20190330194-A1 PYRIDAZINONES AS PARP7 INHIBITORS PARP2, PARP1, PARP4 KDM1A 798/4885MAOB 758/4885CACNB4 4800/4885
US-11014913-B2 Pyridazinones as PARP7 inhibitors PARP2, PARP1, PARP4 KDM1A 798/4885MAOB 758/4885CACNB4 4800/4885
US-11566020-B1 Pyridazinones as PARP7 inhibitors PARP2, PARP1, PARP4 KDM1A 798/4885MAOB 758/4885CACNB4 4800/4885
US-10870641-B2 Pyridazinones as PARP7 inhibitors PARP2, PARP1, PARP4 KDM1A 798/4885MAOB 758/4885CACNB4 4800/4885
US-20230192664-A1 PYRIDAZINONES AS PARP7 INHIBITORS PARP2, PARP1, PARP4 KDM1A 798/4885MAOB 758/4885CACNB4 4800/4885
US-20200123134-A1 PYRIDAZINONES AS PARP7 INHIBITORS PARP2, PARP1, PARP4 KDM1A 798/4885MAOB 758/4885CACNB4 4800/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.